ProCE Banner Activity

Focus on Therapy for MET Exon 14 Mutations in Advanced NSCLC

Multimedia
Watch experts walk you through the latest on MET inhibition and incorporating MET TKIs into your clinic for patients with METex14 NSCLC in this video roundtable.

Released: August 31, 2020

Expiration: August 30, 2021

No longer available for credit.

Share

Faculty

Gregory J. Riely

Gregory J. Riely, MD, PhD

Associate Attending Physician
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Enriqueta Felip

Enriqueta Felip, MD

Head, Thoracic Oncology Unit
Oncology Service
Vall d Hebron University Hospital
Barcelona, Spain

Paul K. Paik

Paul K. Paik, MD

Assistant Attending
Clinical Director, Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

This educational activity is supported by an independent grant from the Healthcare business of

Merck KGaA

Learning Objectives

  • Describe the rationale for METex14 as a targetable alteration in NSCLC
  • Discuss the available clinical evidence for selective MET inhibitors in METex14-altered NSCLC, including an assessment of relative efficacy and central nervous system responses
  • Appropriately manage treatment-related adverse events associated with MET targeted agents used in patients with advanced-stage NSCLC

Program Director Disclosure

Program Director

Gregory J. Riely, MD, PhD

Associate Attending Physician
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Gregory J. Riely, MD, PhD, has disclosed that he has received funds for research support from Mirati, Novartis, Pfizer, Roche, and Takeda.

Faculty Disclosure

Primary Author

Enriqueta Felip, MD

Head, Thoracic Oncology Unit
Oncology Service
Vall d Hebron University Hospital
Barcelona, Spain

Enriqueta Felip, MD, has disclosed that she has received funds for research support from Fundación Merck Salud; consulting fees from AbbVie, AstraZeneca, Bayer, Blueprint Medicines, Boehringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Guardant Health, Janssen, Lilly, Merck KGaA, Novartis, Pfizer, Roche, Samsung, and Takeda; fees for non-CME/CE services from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Lilly, Merck Sharp & Dohme, Novartis, Pfizer, Roche, and Takeda; and other financial or material support from Grífols.

Paul K. Paik, MD

Assistant Attending
Clinical Director, Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

Paul K. Paik, MD, has disclosed that he has received funds for research support from EMD Serono and consulting fees from AstraZeneca, Calithera, Celgene, EMD Serono, and Takeda.

Staff Disclosure

Staff

Rachael M. Andrie, PhD

Clinical Editor

Rachael M. Andrie, PhD, has no relevant conflicts of interest to report.

Marie N. Becker, PhD

Scientific Director

Marie N. Becker, PhD, has no relevant conflicts of interest to report.

Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no relevant conflicts of interest to report.

Katie Eustace, MBA

Senior Director, Global Medical Education, Europe

Katie Eustace, MBA, has no relevant conflicts of interest to report.

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

Justine Stanley, MSc

Editorial Contributor

Justine Stanley, MSc, has no relevant conflicts of interest to report.